Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.

abstract：:Capecitabine is an oral prodrug of 5-fluorouracil. It is being increasingly used in the treatment of colorectal cancer in both the adjuvant and metastatic settings. This review aims to explore the data in relation to the pharmacology and mode of action of capecitabine, followed by an in-depth review of the available c...

journal_title：Expert review of anticancer therapy

authors： Kelly C,Cassidy J

更新日期：2007-06-01 00:00:00

abstract：:Cancer cells generally maintain their survival by suppressing apoptosis. Mitochondrial mechanisms are involved in most forms of apoptosis (referred to as mitochondrial apoptosis), and the Bcl-2 family controls apoptosis at the mitochondrion via a balance of the effects of pro- and antiapoptotic members. Antiapoptotic ...

journal_title：Expert review of anticancer therapy

authors： Gardner CR

更新日期：2004-12-01 00:00:00

abstract：:Defined by its high level of accuracy and rapid radiation dose fall-off, radiosurgery has emerged as an effective radiation technique over the past few decades. Although it was once limited to conditions of the brain, head and neck regions, technological advances in computing and imaging have allowed the application o...

journal_title：Expert review of anticancer therapy

authors： Hara W,Soltys SG,Gibbs IC

更新日期：2007-11-01 00:00:00

abstract：:Testicular germ cell tumors are the most frequent solid tumor to affect young adult males and are increasing in incidence for reasons that are poorly understood. Increasingly, patients present with localized disease where disease-specific survival approaches 100%. Even in the presence of metastatic disease, the majori...

journal_title：Expert review of anticancer therapy

authors： Gilbert DC,Van As NJ,Huddart RA

更新日期：2009-02-01 00:00:00

abstract：:In clinical practice, approximately 50% of new cases of breast cancer occur in women over the age of 65 years, although very few elderly women have been enrolled in the numerous randomized trials conducted so far. Notwithstanding less aggressive biologic features compared with younger patients, breast cancer impacts o...

journal_title：Expert review of anticancer therapy

authors： Basso U,Brunello A,Pogliani C,Monfardini S

更新日期：2004-04-01 00:00:00

abstract：:For more than 25 years, the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was considered the 'gold standard' for the treatment of aggressive lymphomas, 90% of which are diffuse large B-cell lymphomas (DLBCLs). After the demonstration of rituximab's single-agent activity in DLBCL, a pi...

journal_title：Expert review of anticancer therapy

authors： Murawski N,Zwick C,Pfreundschuh M

更新日期：2010-03-01 00:00:00

abstract：:Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy and safety of initial adjuvant therapy with letrozole or anastrozole versus the previous standard of 5 years of adjuvant tamo...

journal_title：Expert review of anticancer therapy

authors： Bria E,Carlini P,Cuppone F,Vaccaro V,Milella M,Cognetti F

更新日期：2010-08-01 00:00:00

abstract：:Introduction: Pembrolizumab is an immune checkpoint inhibitor with high specificity for binding to the programmed cell death 1 (PD-1) receptor. It has been approved by the FDA in patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express the programmed ...

journal_title：Expert review of anticancer therapy

authors： De Felice F,Giudice E,Bolomini G,Distefano MG,Scambia G,Fagotti A,Marchetti C

更新日期：2020-11-26 00:00:00

abstract：:More than 13,000 patients died from invasive bladder cancer in 2005 alone. Radical cystectomy is the most commonly prescribed treatment for patients with muscle-invasive bladder cancer, or for those with a nonmuscle-invasive disease that is refractory to intravesical therapy. Despite advances in surgical technique and...

journal_title：Expert review of anticancer therapy

authors： Amiel GE,Lerner SP

更新日期：2006-02-01 00:00:00

abstract：:Although testicular cancer is currently a rare disease, the incidence is rising. The most important risk factor remains cryptorchism and there is a variable association with testicular microlithiasis. Serum tumor markers remain important for diagnosis, and they have prognostic value and can be used to monitor therapy ...

journal_title：Expert review of anticancer therapy

authors： Balk C,Witjes JA

更新日期：2004-08-01 00:00:00

abstract：INTRODUCTION:Most germ cell cancer patients with metastatic disease are cured by cisplatin-based combination chemotherapy. 30% of metastatic patients will develop relapse or progress despite adequate first-line treatment and will require salvage therapy, with about 10% of metastasized patients ultimately developing pla...

journal_title：Expert review of anticancer therapy

authors： Oing C,Seidel C,Bokemeyer C

更新日期：2018-04-01 00:00:00

abstract：:Non-small cell lung cancer (NSCLC) patients with metastases limited in site and number, termed oligometastases, may represent a unique subpopulation of advanced NSCLC with improved prognosis. The optimal management of these patients remains unclear with the treatment approach currently undergoing a paradigm shift. The...

journal_title：Expert review of anticancer therapy

authors： Bergsma DP,Salama JK,Singh DP,Chmura SJ,Milano MT

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:The term 'morphomics' stands for the markers of body composition in muscle and adipose tissues. in recent years, as part of clinical cancer research, several associations between morphomics and outcome or toxicity were found in different treatment settings leading to a growing interest. we aim to review st...

journal_title：Expert review of anticancer therapy

authors： Bayar MA,Antoun S,Lanoy E

更新日期：2017-04-01 00:00:00

abstract：:Metastasis is the spread of cells from a primary tumor to a distant site, where they arrest and grow to form a secondary tumor. Conventional metastasis models have focused primarily on analysis of end point tumor formation following inoculation with tumor cells. This approach can be used to measure the metastatic pote...

journal_title：Expert review of anticancer therapy

authors： MacDonald IC,Chambers AF

更新日期：2006-09-01 00:00:00

abstract：:The desmoid tumors (DTs) are unusual soft-tissue tumors that have a propensity for aggressive local growth and may develop during, or soon after pregnancy. Pregnancy-associated DTs are uncommon and optimal management of this tumor has yet to be defined. Currently, controversy centers on the timing of surgical resectio...

journal_title：Expert review of anticancer therapy

authors： Johner A,Tiwari P,Zetler P,Wiseman SM

更新日期：2009-11-01 00:00:00

abstract：:Borderline ovarian tumors (BOTs) are epithelial tumors of the ovaries characterized by cellular proliferation and nuclear atypia but without an infiltrative growth pattern. As they frequently affect younger patients the clinical management is complicated by considerations such as preserving fertility and reducing post...

journal_title：Expert review of anticancer therapy

authors： Trillsch F,Mahner S,Ruetzel J,Harter P,Ewald-Riegler N,Jaenicke F,du Bois A

更新日期：2010-07-01 00:00:00

abstract：:Sophia Maprayil, Commissioning Editor for Expert Review of Anticancer Therapy, talks to Dr Iain Frame, Director of Research for Prostate Cancer UK. Iain is Prostate Cancer UK's first Director of Research, responsible for overseeing the development and implementation of the charity's ambitious new research strategy. He...

journal_title：Expert review of anticancer therapy

authors： Frame I,Maprayil S

更新日期：2014-11-01 00:00:00

abstract：:The retinoblastoma (RB)-Cyclin (CCN)D1-p16 cell cycle pathway has a crucial role in lung tumorigenesis. Impairment of the RB pathway has been shown to occur in almost all lung tumors. A deregulation at any level of this core RB pathway seems to make cells insensitive to the mitogenic signaling that is required for cel...

journal_title：Expert review of anticancer therapy

authors： Wikman H,Kettunen E

更新日期：2006-04-01 00:00:00

abstract：:Dietary factors and other naturally occurring substances may emerge as potent therapeutic or preventative agents in the battle against prostate cancer. Much of the current support for these agents is epidemiologically based, but new prospective studies are now underway which may support their use in conventional medic...

journal_title：Expert review of anticancer therapy

authors： Ward JF,Blute ML

更新日期：2003-04-01 00:00:00

abstract：:The monoclonal antibody against HER2, trastuzumab (Herceptin), has become an important player in the treatment of patients with HER2-positive breast cancer. Both in the metastatic and adjuvant setting, the addition of trastuzumab to other systemic treatments has led to a striking increase in tumor response and surviva...

journal_title：Expert review of anticancer therapy

authors： Perik PJ,de Korte MA,van Veldhuisen DJ,Gietema JA,Sleijfer DT,de Vries EG

更新日期：2007-12-01 00:00:00

abstract：:Satraplatin is a novel, orally bioavailable, platinum anticancer drug. Platinum analogs form the mainstay of treatment for a number of cancers, including lung, ovarian, colorectal and head and neck cancer. A disadvantage of the currently marketed platinum analogs is that they must all be administered via intravenous i...

journal_title：Expert review of anticancer therapy

authors： Choy H

更新日期：2006-07-01 00:00:00

abstract：INTRODUCTION:In the recent years, melanoma patients' outcome and survival improved, mainly because of systemic treatment improvement with targeted therapy and checkpoint blockade. Targeted therapy with BRAF and MEK inhibitors was approved to treat patients with unresectable or metastatic melanoma, harboring BRAF V600 m...

journal_title：Expert review of anticancer therapy

authors： Amaral T,Nouri N,Garbe C

更新日期：2016-07-01 00:00:00

abstract：:Advanced pancreatic adenocarcinoma historically has a poor prognosis and the mortality rate has remained unchanged for over a decade. Common treatment options for patients with advanced pancreatic cancer include chemoradiation and/or chemotherapy. Single-agent gemcitabine has been considered the standard of care since...

journal_title：Expert review of anticancer therapy

authors： Warsame R,Grothey A

更新日期：2012-10-01 00:00:00

abstract：:In breast cancer, RANK ligand (RANKL) appears to play an important role in the process of chemotaxis between circulating tumor cells and the bone microenvironment, which enables RANK-expressing breast cancer cells to migrate into the bone. Mounting clinical evidence has further demonstrated that the anti-RANKL monoclo...

journal_title：Expert review of anticancer therapy

authors： Azim H,Azim HA Jr

更新日期：2013-02-01 00:00:00

abstract：:Anticancer therapy relies on targeting highly proliferative cells. Commonly used chemotherapy does not selectively target individual cancer cells. The identification of distinct cancer stem cells that have the unique ability to engraft tumors and maintain cancer self-renewal may prove vital in the development of novel...

journal_title：Expert review of anticancer therapy

authors： Klotz D

更新日期：2013-04-01 00:00:00

abstract：:There is increasing interest in the use of prognostic markers that may predict survival and guide management in patients diagnosed with the early stages of chronic lymphocytic leukemia (CLL). Currently, the most important traditional prognostic factors include clinical staging, lymphocyte doubling time and β2-microglo...

journal_title：Expert review of anticancer therapy

authors： Bazargan A,Tam CS,Keating MJ

更新日期：2012-03-01 00:00:00

abstract：:Subungual melanoma (SUM) is infrequent in the general population, accounting for 0.7-3.5% of all cutaneous melanomas. SUM absolute incidence is similar among different racial groups; however, the relative proportion among overall cutaneous melanoma cases within each population varies in relation to the frequency of su...

journal_title：Expert review of anticancer therapy

authors： De Giorgi V,Saggini A,Grazzini M,Gori A,Rossari S,Scarfì F,Verdelli A,Chimenti S,Lotti T,Massi D

更新日期：2011-05-01 00:00:00

abstract：:Malignant pleural mesothelioma is an aggressive fatal malignancy with a prognosis that has not significantly improved in the last decades. This review summarizes the current state of treatment and the various attempts that are made to improve overall survival for patients with malignant pleural mesothelioma. It also d...

journal_title：Expert review of anticancer therapy

authors： Schunselaar LM,Quispel-Janssen JM,Neefjes JJ,Baas P

更新日期：2016-01-01 00:00:00

abstract：:Androgen deprivation therapy is the standard of care for the initial treatment of metastatic prostate cancer. However, the majority of these patients live long enough to experience disease progression despite castration. This scenario is defined as castration-resistant prostate cancer (CRPC) and has a poor outcome and...

journal_title：Expert review of anticancer therapy

authors： Gaya JM,Ahallal Y,Sanchez-Salas R,Barret E,Rozet F,Galiano M,Macek P,Durand M,Cerruti J,Prapotnich D,Ropert S,Bennamoun M,Cathelineau X

更新日期：2013-07-01 00:00:00

abstract：INTRODUCTION:The development of immune-checkpoint inhibitors targeting the programmed death-1 (PD-1) and its ligand (PD-L1) axis has transformed the treatment paradigm in non-small-cell lung cancer, bringing about unprecedented 5-year survival rates. Despite this dramatic improvement, roughly 70% of patients do not der...

journal_title：Expert review of anticancer therapy

authors： Alex F,Alfredo A

更新日期：2020-11-01 00:00:00